Abstract
At homeostasis, vascular cells display a very low proliferative rate and a scant migratory activity. However, hyperplastic growth and locomotion of vascular cells are a hallmark of vascular remodeling during several pathophysiological conditions (e. g., neovascularization, arteriosclerosis and restenosis post-angioplasty). Thus, a better understanding of the molecular mechanisms that control vascular cell proliferation and migration should facilitate the development of novel therapies to treat cardiovascular disease. In this review, we will discuss recent studies implicating the cell cycle regulatory protein p27Kip1 as a key modulator of vascular cell growth and locomotion in vitro and during vascular remodeling in vivo.
Keywords: atherosclerosis, restenosis, neovascularization, proliferation, migration, p27
Current Vascular Pharmacology
Title: Role of the Growth Suppressor p27Kip1 During Vascular Remodeling
Volume: 1 Issue: 1
Author(s): Antonio Díez-Juan, Claudia Castro, M. D. Edo and Vicente Andrés
Affiliation:
Keywords: atherosclerosis, restenosis, neovascularization, proliferation, migration, p27
Abstract: At homeostasis, vascular cells display a very low proliferative rate and a scant migratory activity. However, hyperplastic growth and locomotion of vascular cells are a hallmark of vascular remodeling during several pathophysiological conditions (e. g., neovascularization, arteriosclerosis and restenosis post-angioplasty). Thus, a better understanding of the molecular mechanisms that control vascular cell proliferation and migration should facilitate the development of novel therapies to treat cardiovascular disease. In this review, we will discuss recent studies implicating the cell cycle regulatory protein p27Kip1 as a key modulator of vascular cell growth and locomotion in vitro and during vascular remodeling in vivo.
Export Options
About this article
Cite this article as:
Díez-Juan Antonio, Castro Claudia, Edo D. M. and Andrés Vicente, Role of the Growth Suppressor p27Kip1 During Vascular Remodeling, Current Vascular Pharmacology 2003; 1 (1) . https://dx.doi.org/10.2174/1570161033386709
DOI https://dx.doi.org/10.2174/1570161033386709 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims
Current Cancer Therapy Reviews Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design Regulation of Catechins in Uric Acid Metabolism Disorder Related Human Diseases
Mini-Reviews in Medicinal Chemistry Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Current Pharmaceutical Design CuFe<sub>2</sub>O<sub>4</sub> Nanoparticle Mediated Method for the Synthesis of 5-Substituted 1H-Tetrazoles from (E)-Aldoximes
Letters in Organic Chemistry Determination of Phytochemicals by GC-MS in Two Fractions (17 and 21) of Methanol Extract of Loranthus Micranthus and their Antioxidant and Anti-Inflammatory Activity
The Natural Products Journal Hydrolyzates of Silkworm Pupae (Bombyx Mori) Protein is a New Source of Angiotensin I-Converting Enzyme Inhibitory Peptides(ACEIP)
Current Pharmaceutical Biotechnology Metabolic Syndrome: Sex-Related Cardiovascular Risk and Therapeutic Approach
Current Medicinal Chemistry Nitric Oxide Pathway as New Drug Targets for Refractory Hypertension
Current Pharmaceutical Design The Role of Diet in Patients with Metabolic Syndrome
Current Medicinal Chemistry VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Health Disparities in Women's Health: Current Findings and Future Directions
Current Women`s Health Reviews Management of Cardiovascular Risk Factors in Patients with Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews Microalgal Fatty Acids and Their Implication in Health and Disease
Mini-Reviews in Medicinal Chemistry The Pathophysiological Basis of Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension
Current Vascular Pharmacology Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?
Current Vascular Pharmacology Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Current Cardiology Reviews